Systemic Lupus Clinical Trial
Official title:
Improvement of Medication Adherence in Adolescents With SLE Using Web-based Education With and Without a Social Media Intervention
Verified date | July 2017 |
Source | Milton S. Hershey Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study was to examine the effect of an online educational program with and without a social media experience.The primary goal of this study was to determine whether medication adherence would be improved by having adolescents and young adults with systemic lupus erythematosus participate in an online educational website, with or without a social media experience. The secondary goal was to determine whether secondary outcomes such as quality of life, stress, and self-efficacy improved in this model, and whether these changes were associated with improvements in medication management.
Status | Completed |
Enrollment | 37 |
Est. completion date | January 31, 2015 |
Est. primary completion date | January 31, 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 13 Years to 23 Years |
Eligibility |
Inclusion Criteria: - age between 13 and 23 at the time of recruitment - having the diagnosis of SLE made or confirmed by a pediatric or adult rheumatologist at Penn State Children's Hospital/Hershey Medical Center - having regular internet access. Exclusion Criteria: - age <13 or >23 years - comorbid medical or psychiatric illness that would affect the outcome measures. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center | Children's Miracle Network, Lupus Foundation of America |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Medication Adherence | A medication possession ratio was calculated based on fill date information from the subjects' pharmacies | 6 months | |
Secondary | Stress utilizing the Perceived Severity of Stress Questionnaire | Stress was measured by the Perceived Severity of Stress Questionnaire (PSQ) | 14 weeks | |
Secondary | Self-efficacy utilizing the Children's Arthritis Self-Efficacy scale | Self-efficacy was measured using the Children's Arthritis Self-Efficacy scale (CASE) which was modified slightly for systemic lupus | 14 weeks | |
Secondary | Quality of Life utilizing the Simple Measure of the Impact of Lupus Erythematosus in Youngsters (SMILEY) index | Quality of life was assessed using the validated Simple Measure of the Impact of Lupus Erythematosus in Youngsters (SMILEY) index | 14 weeks | |
Secondary | Sense of agency | Sense of agency (SOA) was measured via three Likert scale questions aimed to tap three core concepts of agency: competence ("Blogging… makes me feel I have control over my own voice"), assertiveness ("…enables me to assert myself"), and confidence ("…makes me feel I have a distinct voice") | 14 weeks | |
Secondary | Sense of community | Sense of community (SOC) was measured using a 22-item scale (8, 9, 20). SOC consists of feelings of belonging to the community, having influence on, and being influenced by, the community, being supported by the community while also supporting them; and feelings of shared emotional connection. | 14 weeks | |
Secondary | Empowerment | Empowerment was assessed using a validated quantitative Likert scale tool that measured 1) "empowering processes" (Appendix A), and 2) "empowering outcomes" | 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03749044 -
ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies
|
N/A | |
Not yet recruiting |
NCT03752983 -
Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|
||
Recruiting |
NCT03819777 -
Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)
|
||
Recruiting |
NCT04894253 -
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
|
||
Not yet recruiting |
NCT03164720 -
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
|
||
Completed |
NCT03762824 -
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
|
Phase 4 | |
Not yet recruiting |
NCT06435468 -
Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases
|
N/A | |
Terminated |
NCT01738360 -
Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)
|
Phase 2 | |
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT04108611 -
Immune Adsorption Role in Treatment of Resistant Lupus
|
N/A | |
Not yet recruiting |
NCT04256577 -
Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment
|
||
Completed |
NCT03540823 -
Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases
|
Phase 4 |